Study shows medical biotechnology flourishing in Germany
A Boston Consulting Group (BCG) report indicates that Germany's medical biotechnology industry continues to grow and increase its market share. The survey found that biopharmaceuticals earned EUR 12.7 billion in revenue 2019, or 13 percent more than in the previous year, while the entire pharmaceuticals market grew nearly seven percent in the same period.
The report entitled Medizinische Biotechnologie in Deutschland 2020 (Medical Biotechnology in Germany 2020), adds that while all fields of application expanded, the revenue share of biopharmaceuticals grew from 27.1 percent to 28.7 percent. At the same time, the sector had 15 new biopharmaceuticals licensed in 2019, to account for 45 percent of all new approvals.
Vfa-bio, which represents the biotechnology interests of the Association of Research-Based Pharmaceutical Companies (vfa), publishes the report annually. When the 2020 edition was released, vfa-bio chairman and CEO of Rentschler Biopharma SE Frank Mathias said, "Biopharmaceuticals are successful economically because they meet medical demands." The study observed growth in the need for biopharmaceuticals in all applicable indications. It noted the greatest increases in demand for immunological treatments, followed by oncological therapies, and drugs for metabolic disorders.
Also featured in the report were biosimilars – officially approved versions of original "innovator" products that can be manufactured when the original product's patent expires. Some of these products achieved market shares of up to 60 percent in the first year of their release.
These figures reflect the ongoing vitality of medical biotechnology in Germany, which is based on decades of experience in the field, synergies between basic research and industry, and government support, among other things. The country's response to the SARS-CoV-2 pandemic illustrates this. BCG notes that Germany is among those running a particularly large number of vaccine development projects, including for mRNA and DNA-based products, an area where Germany is known as a global leader.
The export initiative for the German healthcare industry, HEALTH MADE IN GERMANY, is the place to learn more about this dynamic sector. The initiative has published the German Medical Biotechnology Industry Profile and has produced a video Medical Biotechnology Made-in-Germany to provide information on German medical biotech for interested individuals and businesses from abroad.